NSSC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That NAPCO Security Technologies, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired NAPCO securities between February 5, 2024 and February 3, 2025, both dates inclusive (the 'Class Period'). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/NSSC.
Case Details
The complaint alleges that Defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of NAPCO's ability to forecast the demand for its products or otherwise the true state of NAPCO's negotiating position with distributors; notably, that, despite making lofty long-term projections and claiming one-off setbacks to hardware sales, NAPCO's forecasting processes fell short as sales continued to decline and, ultimately, derailed the Company's long-term projections. The Complaint adds that such statements absent these material facts caused Plaintiff and other shareholders to purchase NAPCO's securities at artificially inflated prices.
What's Next?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/NSSC. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660 . If you suffered a loss in NAPCO you have until June 24, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn , X , Facebook , or Instagram .
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call
Company will host conference call at 4:30 p.m. ET, on Tuesday, August 12, 2025 CELEBRATION, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the second quarter 2025 on Tuesday, August 12, 2025, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be accessible on the 'Events & Presentations' page in the Investor Relations section of Zevra's website at To join via telephone, please use the following dial-in information: (800) 245-3047 (United States) +1 (203) 518-9765 (International) Conference ID: ZVRAQ225 A replay of the webcast will be available for 90 days beginning at approximately 5:30 p.m. ET. The replay will be accessible on the 'Events & Presentations' page of Zevra's website at About Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. is a commercial-stage company combining science, data, and patient needs to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community. For more information, please visit or follow us on X and LinkedIn. Caution Concerning Forward-Looking Statements This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra's participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra's Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 12, 2025, and Zevra's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed on May 13, 2025, and Zevra's other filings with the SEC. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release. Zevra Contact Nichol Ochsner +1 (732) 754-2545 nochsner@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Lindblad Expeditions (NASDAQ:LIND) Delivers Impressive Q2, Stock Soars
Cruise and exploration company Lindblad Expeditions (NASDAQ:LIND) reported Q2 CY2025 results exceeding the market's revenue expectations , with sales up 23% year on year to $167.9 million. The company expects the full year's revenue to be around $737.5 million, close to analysts' estimates. Its GAAP loss of $0.18 per share was 21.7% above analysts' consensus estimates. Is now the time to buy Lindblad Expeditions? Find out in our full research report. Lindblad Expeditions (LIND) Q2 CY2025 Highlights: Revenue: $167.9 million vs analyst estimates of $159 million (23% year-on-year growth, 5.6% beat) EPS (GAAP): -$0.18 vs analyst estimates of -$0.23 (21.7% beat) Adjusted EBITDA: $24.84 million vs analyst estimates of $12.48 million (14.8% margin, 99% beat) The company lifted its revenue guidance for the full year to $737.5 million at the midpoint from $725 million, a 1.7% increase EBITDA guidance for the full year is $111.5 million at the midpoint, above analyst estimates of $107.6 million Operating Margin: 2.6%, up from -6% in the same quarter last year Free Cash Flow Margin: 8%, similar to the same quarter last year Market Capitalization: $641.7 million Natalya Leahy, Chief Executive Officer, said "I'm incredibly proud of the team's accomplishments this quarter. We delivered 23% revenue growth, achieved 86% occupancy on a 5% increase in capacity, and drove a 139% increase in Adjusted EBITDA. These results reflect strong momentum behind our strategic initiatives. We remain focused on unlocking meaningful value through continued revenue growth and disciplined cost innovation, and we are confident in the direction we're heading." Company Overview Founded by explorer Sven-Olof Lindblad in 1979, Lindblad Expeditions (NASDAQ:LIND) offers cruising experiences to remote destinations in partnership with National Geographic. Revenue Growth A company's long-term sales performance can indicate its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Luckily, Lindblad Expeditions's sales grew at an impressive 22.2% compounded annual growth rate over the last five years. Its growth beat the average consumer discretionary company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within consumer discretionary, a stretched historical view may miss a company riding a successful new property or trend. Lindblad Expeditions's annualized revenue growth of 15% over the last two years is below its five-year trend, but we still think the results were respectable. This quarter, Lindblad Expeditions reported robust year-on-year revenue growth of 23%, and its $167.9 million of revenue topped Wall Street estimates by 5.6%. Looking ahead, sell-side analysts expect revenue to grow 9.1% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will see some demand headwinds. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Operating Margin Lindblad Expeditions's operating margin has been trending up over the last 12 months and averaged 3.8% over the last two years. The company's higher efficiency is a breath of fresh air, but its suboptimal cost structure means it still sports lousy profitability for a consumer discretionary business. This quarter, Lindblad Expeditions generated an operating margin profit margin of 2.6%, up 8.6 percentage points year on year. This increase was a welcome development and shows it was more efficient. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Although Lindblad Expeditions's full-year earnings are still negative, it reduced its losses and improved its EPS by 18.3% annually over the last five years. The next few quarters will be critical for assessing its long-term profitability. In Q2, Lindblad Expeditions reported EPS at negative $0.18, up from negative $0.48 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street is optimistic. Analysts forecast Lindblad Expeditions's full-year EPS of negative $0.30 will reach break even. Key Takeaways from Lindblad Expeditions's Q2 Results We were impressed by how significantly Lindblad Expeditions blew past analysts' EBITDA expectations this quarter. We were also glad its EPS outperformed Wall Street's estimates. On the other hand, its full-year revenue guidance was in line. Overall, we think this was a solid quarter with some key areas of upside. The stock traded up 8.3% to $12.72 immediately after reporting. Indeed, Lindblad Expeditions had a rock-solid quarterly earnings result, but is this stock a good investment here? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free.
Yahoo
8 minutes ago
- Yahoo
Bruker (NASDAQ:BRKR) Reports Sales Below Analyst Estimates In Q2 Earnings
Scientific instrument company Bruker (NASDAQ:BRKR). missed Wall Street's revenue expectations in Q2 CY2025, with sales flat year on year at $797.4 million. The company's full-year revenue guidance of $3.47 billion at the midpoint came in 1.5% below analysts' estimates. Its non-GAAP profit of $0.32 per share was 23.4% below analysts' consensus estimates. Is now the time to buy Bruker? Find out in our full research report. Bruker (BRKR) Q2 CY2025 Highlights: Revenue: $797.4 million vs analyst estimates of $809.2 million (flat year on year, 1.5% miss) Adjusted EPS: $0.32 vs analyst expectations of $0.42 (23.4% miss) Adjusted EBITDA: $68 million vs analyst estimates of $123.6 million (8.5% margin, 45% miss) The company dropped its revenue guidance for the full year to $3.47 billion at the midpoint from $3.52 billion, a 1.4% decrease Management lowered its full-year Adjusted EPS guidance to $2 at the midpoint, a 18% decrease Operating Margin: 1.5%, down from 6% in the same quarter last year Free Cash Flow was -$148.8 million compared to -$25.1 million in the same quarter last year Organic Revenue fell 7% year on year (7.4% in the same quarter last year) Market Capitalization: $5.76 billion Company Overview With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ:BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels. Revenue Growth A company's long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Thankfully, Bruker's 11.8% annualized revenue growth over the last five years was decent. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Bruker's annualized revenue growth of 12.6% over the last two years aligns with its five-year trend, suggesting its demand was stable. We can better understand the company's sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don't accurately reflect its fundamentals. Over the last two years, Bruker's organic revenue averaged 4.8% year-on-year growth. Because this number is lower than its two-year revenue growth, we can see that some mixture of acquisitions and foreign exchange rates boosted its headline results. This quarter, Bruker missed Wall Street's estimates and reported a rather uninspiring 0.4% year-on-year revenue decline, generating $797.4 million of revenue. Looking ahead, sell-side analysts expect revenue to grow 3.2% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will face some demand challenges. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating Margin Bruker has done a decent job managing its cost base over the last five years. The company has produced an average operating margin of 12.7%, higher than the broader healthcare sector. Analyzing the trend in its profitability, Bruker's operating margin decreased by 10.9 percentage points over the last five years. This performance was caused by more recent speed bumps as the company's margin fell by 12 percentage points on a two-year basis. We're disappointed in these results because it shows its expenses were rising and it couldn't pass those costs onto its customers. This quarter, Bruker generated an operating margin profit margin of 1.5%, down 4.5 percentage points year on year. This contraction shows it was less efficient because its expenses increased relative to its revenue. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Bruker's remarkable 10.4% annual EPS growth over the last five years aligns with its revenue performance. This tells us it maintained its per-share profitability as it expanded. In Q2, Bruker reported adjusted EPS at $0.32, down from $0.52 in the same quarter last year. This print missed analysts' estimates, but we care more about long-term adjusted EPS growth than short-term movements. Over the next 12 months, Wall Street expects Bruker's full-year EPS of $2.15 to grow 23%. Key Takeaways from Bruker's Q2 Results We struggled to find many positives in these results. Its full-year EPS guidance missed and its EPS fell short of Wall Street's estimates. Overall, this was a weaker quarter. The stock traded down 3.9% to $36.48 immediately following the results. Bruker underperformed this quarter, but does that create an opportunity to invest right now? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
